Bremelanotide (PT-141) (Figure 3B) is a MC4R agonist approved in June of 2019 by the FDA for erectile dysfunction in men and hypoactivity sexual desire disorder in premenopausal women, as characterized by low sexual desire that causes marked distress or interpersonal difficulty [228,229]. Here, MC4R is linked to erectile dysfunction.